Clinical trials using the MEK inhibitor, selumetinib, revealed decreased pNF and spinal neurofibroma burden (Jackson et al., 2020) with minimal side effects (Baldo et al., 2021), and another MEK inhibitor, trametinib, decreased tumor size (Toledano et al., 2021; Weiss et al., 2021). This evidence concerns the gene MAP2K7 and neoplasm.